Focus: Cordis is a Miami Lakes-based medical device company with 5,000+ employees focused on cardiovascular, respiratory, and nephrology interventions, particularly drug-eluting stents and endovascular repair systems. The company operates as a public entity with a substantial clinical trial portfolio spanning multiple therapeutic areas.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cordis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cordis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cordis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device - Fierce Biotech
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device Fierce Biotech
Cordis Wins FDA Nod for Selution SLR Sirolimus-Eluting Balloon - mpo-mag.com
Cordis Wins FDA Nod for Selution SLR Sirolimus-Eluting Balloon mpo-mag.com
Cordis earns FDA nod for Selution SLR drug-eluting balloon - MassDevice
Cordis earns FDA nod for Selution SLR drug-eluting balloon MassDevice
SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US - biospace.com
SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US biospace.com
8-K Filing: Orchestra BioMed Holdings, Inc. (OBIO) (CIK 0001814114) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: HeartSciences Inc. (HSCS, HSCSW) (CIK 0001468492) — AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 27, 2026, BY AND AMONG HEARTSCIENCES INC., CORDIS ACQUISITION, LLC, FORTITUDE MINING HOLDINGS, INC. AND FORTITUDE MINING HOLDCO, LLC
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, DATED AS OF JULY 27, 2026, BY AND AMONG HEARTSCIENCES INC., CORDIS ACQUISITION, LLC, FORTITUDE MINING HOLDINGS, INC. AND FORTITUDE MINING HOLDCO, LLC
Showing 6 of 9 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Music-Based Interventions in Advanced Cancer Palliative Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Identified Within the Broader Field of Art-Based Interventions.
Co-Designing an Easy-Read Adult Social Care Outcomes Measure for Older People: Approach to and Reflections on Involving People Living With Dementia and Their Supporters.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo